NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI® (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test. The effectiveness of XALKORI is based on objective response rates (ORR) and, as XALKORI received accelerated approval from th

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Multiple data presentations for ELIQUIS® (apixaban), an oral direct Factor Xa inhibitor being developed by Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE), will be given at the European Society of Cardiology Congress, August 27-31, 2011, in Paris, France. Globally-conducted registrational studies evaluating ELIQUIS for the prevention of stroke in patients with atrial fibrillation will be presented during the congress. Of note is t

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer’s regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myel

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it has prevailed in its patent infringement action against Teva Pharmaceuticals USA, Inc. in the United States District Court for the Eastern District of Virginia. "We are pleased that the court recognized the validity and enforceability of our Viagra patent for the treatment of erectile dysfunction," said Amy Schulman, executive vice president and general counsel for Pfizer. "Protecting the intellectual property rights of our innovativ

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it will partner with University of California, San Diego Health Sciences through the company’s Centers for Therapeutic Innovation (CTI), a network of collaborative partnerships with top-tier life science research institutions in California, Massachusetts and New York that aims to accelerate and transform drug discovery and development. Pfizer anticipates a potential investment of up to $50 million over the next five years. This sum is a

NEW YORK--(BUSINESS WIRE)--For more than 25 years, Caltrate® has helped replenish the calcium and vitamin D women need each day in order to keep their bodies active—so they can move the world physically, emotionally and for the causes in which they believe. This year, Caltrate® is partnering with Dana Delany to celebrate women who move our world by issuing a national call-to-action inviting women everywhere to share their individual stories and everyday accomplishments. As part of this celebrati

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--NCCN receives $2M educational grant from Pfizer to support first CME program to measure impact on patient outcomes & clinician performance through data collected in the NCCN Database for Breast Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE):   ($ in millions, except per share amounts)   Second-Quarter     Year-to-Date 2011   2010   Change 2011   2010   Change Reported Revenues $ 16,984 $ 17,132 (1 %) $ 33,486 $ 33,708 (1 %) Adjusted Income(2) 4,726 4,927 (4 %) 9,534 9,789 (3 %) Adjusted Diluted EPS(2) 0.60 0.61 (2 %) 1.19 1.21 (2 %) Reported Net Income(3) 2,610 2,475 5 % 4,832 4,501 7 % Reported Diluted EPS(3) 0.33 0.31 6 % 0.61 0.56 9 %   See end of text prior to tables for notes.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed the sale of its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. L.P. (together with its affiliates, “KKR”), following the receipt of required regulatory clearances, including in the U.S. and the European Union. Under the terms of the previously announced agreement, KKR acquired the Capsugel business for $2.375 billion in cash. Pfizer’s financial advisors for the transaction were Morgan

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company’s supplemental Biologics License Application (sBLA) for use of Prevnar 13®, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in adults aged 50 and older. This extends the review period to January 2012. The extension is due to additional data that Pfizer elected to submit from two studies that were